Get the Stockscreener App
2.05
0.97%
-0.02
Ensysce Biosciences Inc stock is traded at $2.05, with a volume of 73,346.
It is down -0.97% in the last 24 hours and down -6.82% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$2.07
Open:
$2.07
24h Volume:
73,346
Relative Volume:
0.20
Market Cap:
$6.09M
Revenue:
-
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.6811
EPS:
-3.01
Net Cash Flow:
$-9.78M
1W Performance:
+0.00%
1M Performance:
-6.82%
6M Performance:
-62.04%
1Y Performance:
-66.67%
1-Day Range:
$2.03
$2.115
1-Week Range:
$2.00
$2.13
52-Week Range:
$1.62
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
2.05 | 5.05M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
What to expect from Ensysce Biosciences Inc. in the next 30 daysTrade Volume Summary & Consistent Profit Alerts - Newser
What technical models suggest about Ensysce Biosciences Inc.’s comeback - Newser
Can technical indicators confirm Ensysce Biosciences Inc.’s reversalWeekly Trend Report & Fast Moving Market Watchlists - Newser
Combining price and volume data for Ensysce Biosciences Inc.Chart Signals & Reliable Entry Point Alerts - Newser
Applying Wyckoff theory to Ensysce Biosciences Inc. stockQuarterly Portfolio Summary & Community Consensus Trade Signals - Newser
Short interest data insights for Ensysce Biosciences Inc.Market Risk Report & Reliable Volume Spike Alerts - Newser
What recovery options are there for Ensysce Biosciences Inc.2025 Top Gainers & Reliable Volume Spike Alerts - Newser
What candlestick patterns are forming on Ensysce Biosciences Inc.2025 Price Action Summary & Low Risk Entry Point Tips - Newser
Multi asset correlation models including Ensysce Biosciences Inc.2025 Market WrapUp & Community Trade Idea Sharing - Newser
How to recover losses in Ensysce Biosciences Inc. stockJuly 2025 Trends & Low Risk Growth Stock Ideas - Newser
Earnings visualization tools for Ensysce Biosciences Inc.Dollar Strength & Reliable Breakout Forecasts - Newser
Automated trading signals detected on Ensysce Biosciences Inc.Trend Reversal & Entry and Exit Point Strategies - Newser
Analyzing recovery setups for Ensysce Biosciences Inc. investorsTrade Signal Summary & Daily Momentum Trading Reports - Newser
Identifying reversal signals in Ensysce Biosciences Inc.July 2025 Trade Ideas & Free Real-Time Market Sentiment Alerts - Newser
Can machine learning forecast Ensysce Biosciences Inc. recoveryPrice Action & Daily Stock Momentum Reports - Newser
Geoff Birkett to Chair Fierce New Product Planning Summit 2025, Delivering Opening Remarks and Presenting Case Study on Launching Successful Brands. - AInvest
Pain Medicine Innovation Leader: Ensysce CCO Birkett to Chair Major Product Planning Summit 2025 - Stock Titan
Can Ensysce Biosciences Inc. rally from current levelsWeekly Investment Report & AI Based Buy and Sell Signals - Newser
Can a trend reversal in Ensysce Biosciences Inc. lead to recoveryMarket Sentiment Review & Safe Capital Preservation Plans - Newser
Published on: 2025-08-19 01:25:13 - Newser
What is Ensysce Biosciences Inc.’s TAM (Total Addressable Market)2025 Volatility Report & Real-Time Volume Analysis Alerts - newsyoung.net
Should I trade or invest in Ensysce Biosciences Inc.Portfolio Growth Summary & Low Risk High Win Rate Stock Picks - kangso.co.kr
Q3 EPS Estimate for Ensysce Biosciences Lowered by Analyst - Defense World
Is Ensysce Biosciences Inc. stock poised for growthJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - Newser
Key resistance and support levels for Ensysce Biosciences Inc.2025 Fundamental Recap & AI Powered Trade Plan Recommendations - Newser
Visualizing Ensysce Biosciences Inc. stock with heatmapsTrade Ideas & Free Safe Entry Trade Signal Reports - Newser
Is Ensysce Biosciences Inc. reversing from oversold territory2025 Sector Review & Growth Focused Stock Pick Reports - Newser
Can volume confirm reversal in Ensysce Biosciences Inc.Buy Signal & Safe Capital Preservation Plans - Newser
Will Ensysce Biosciences Inc. outperform its industry peersJuly 2025 Review & Reliable Entry Point Alerts - thegnnews.com
How to manage a losing position in Ensysce Biosciences Inc.Market Growth Summary & Stock Portfolio Risk Control - Newser
Real time alert setup for Ensysce Biosciences Inc. performanceGap Up & Free Technical Confirmation Trade Alerts - Newser
Is Ensysce Biosciences Inc. stock reversal real or fakeJuly 2025 Selloffs & Low Drawdown Investment Strategies - Newser
Intraday pattern recognizer results for Ensysce Biosciences Inc.Breakout Watch & High Accuracy Swing Trade Signals - Newser
Backtesting results for Ensysce Biosciences Inc. trading strategiesJuly 2025 Weekly Recap & High Accuracy Investment Signals - Newser
Will Ensysce Biosciences Inc. rebound enough to break evenSell Signal & Daily Oversold Stock Bounce Ideas - Newser
What Fibonacci levels say about Ensysce Biosciences Inc. reboundJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - Newser
Best data tools to analyze Ensysce Biosciences Inc. stockProduct Launch & Fast Momentum Entry Tips - Newser
Ensysce Biosciences Inc. stock outlook for YEARQuarterly Performance Summary & Precise Entry and Exit Recommendations - Newser
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):